Evidence map›Paper›PMID 30271406›Full record

ArticleFrontiers in immunology2018

Porous Nanoparticles With Self-Adjuvanting M2e-Fusion Protein and Recombinant Hemagglutinin Provide Strong and Broadly Protective Immunity Against Influenza Virus Infections.

Valentina Bernasconi, Beatrice Bernocchi, Liang Ye, Minh Quan Lê, Ajibola Omokanye, Rodolphe Carpentier, Karin Schön, Xavier Saelens, Peter Staeheli, Didier Betbeder and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. The Quest for a Truly Universal Influenza Vaccine.Frontiers in cellular and infection microbiology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 4 countries.

Valentina BernasconiMucosal Immunobiology and Vaccine Center, Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Beatrice BernocchiLille Inflammation Research International Center - U995, University of Lille, INSERM and CHU Lille, Lille, France.
Liang YeInstitute of Virology, University Medical Center Freiburg, Freiburg, Germany.
Minh Quan LêLille Inflammation Research International Center - U995, University of Lille, INSERM and CHU Lille, Lille, France.
Ajibola OmokanyeMucosal Immunobiology and Vaccine Center, Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Rodolphe CarpentierLille Inflammation Research International Center - U995, University of Lille, INSERM and CHU Lille, Lille, France.
Karin SchönMucosal Immunobiology and Vaccine Center, Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Xavier SaelensVIB-UGent Center for Medical Biotechnology, Ghent, Belgium.
Peter StaeheliInstitute of Virology, University Medical Center Freiburg, Freiburg, Germany.
Didier BetbederLille Inflammation Research International Center - U995, University of Lille, INSERM and CHU Lille, Lille, France.
Nils LyckeMucosal Immunobiology and Vaccine Center, Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
University of Gothenburg · SEInserm · FRUniversity Medical Center Freiburg · DEGhent University · BELille Inflammation Research International Center · FRUniversité de Lille · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to the high risk of an outbreak of pandemic influenza, the development of a broadly protective universal influenza vaccine is highly warranted. The design of such a vaccine has attracted attention and much focus has been given to nanoparticle-based influenza vaccines which can be administered intranasally. This is particularly interesting since, contrary to injectable vaccines, mucosal vaccines elicit local IgA and lung resident T cell immunity, which have been found to correlate with stronger protection in experimental models of influenza virus infections. Also, studies in human volunteers have indicated that pre-existing CD4

Indexed as

Orthomyxoviridae InfectionsAnimalsCD4-Positive T-LymphocytesFemaleHemagglutinin Glycoproteins, Influenza VirusInfluenza A virusInfluenza VaccinesMaleMiceMice, Inbred BALB CNanoparticlesPorosityRecombinant Fusion ProteinsViral Matrix ProteinsHemagglutinin Glycoproteins, Influenza Virushemagglutinin, human influenza A virusInfluenza VaccinesM1 protein, Influenza A virusRecombinant Fusion ProteinsViral Matrix ProteinsCTA1-DDinfluenza A virusmaltodextrin nanoparticlesmucosal vaccinationnasal immunizationtargeted adjuvantUniversal vaccine

Identifiers

PMID30271406
PMCPMC6146233
OpenAlexW2890950978

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.